Dr. Ahmed Bouzidi, Angine Partner in EU.He is also Senior Associate of the Royal Society of Medicine (London). Until recently, he was the CEO of Vaxeal Holding SA, biotech SME specialized in Immuno-Oncology, President of the European Biopharmaceutical Enterprises (Brussels), the European Trade Association representing biopharmaceutical companies from innovative SMEs to worldwide leaders, and board member of Vaccines Europe. He previously founded and managed SEDAC-Therapeutics inc., a leading biotech pioneer in peptide-based immunotherapies (exit by Leveraged Buy Out), and Biophysiomics inc. (acquired by Kuachang Science & Technology, China). He held senior advisory positions with high-level Chinese healthcare stakeholders (Public & Private Institutions), and worked for 10 years as a Senior Researcher at the LFB (France). Ahmed holds a Master degree in Animal Biology from University of Lille (France) and a PhD in Cellular Biology and an MBA from University of New Hampshire, Durham (USA). His executive management experience in the biotechnology industries spans more than 25 years.

Angine's Partner in the North American Region. Dr. Zhang is an accomplished scientist in Preclinical Biology within the pharmaceutical industry, specializing in cutting-edge next-generation technologies, and heholds a PhD in Biochemistry from a joint-doctoral program by the International Center for Genetic Engineering and Biotechnology (ICGEB), Italy and He completed his Postdoctoral training at the University of Pittsburgh/University of Alabama in 2000. With over years of experience, Dr. Zhang has a proven track record as a senior biologist and Study Director of Preclinical Biology at a prominent US-based biotech company with one new durg successfully launched.In addition to his scientific contributions, Dr. Zhang held the position of CSO and Business BD Head at a leading pharmaceutical company in China for nearly 6 years. His exceptional leadership skills were evident as he successfully secured more than 4 cross-border partnership projects through diverse models such as license-in, equity investment, and co-development.Currently, Dr. Zhang serves as Angine's Partner in the North American region, where he plays a pivotal role in Angine's Global BD team. He actively contributes to project license-in/out and co-development initiatives, leveraging his extensive expertise in scientific evaluation, business development, and strategic partnerships.

Angine Partner in South East Asia market.Chuan has over 30 years of experience in the pharmaceutical and medical device industry and has worked in the industry in China, New Zealand, Australia, Singapore and other ASEAN countries. Chuan has held senior positions in the areas of Quality Assurance, Regulatory Compliance and Regulatory Affairs in Merck, Wyeth, and Pfizer. He has been responsible for maintenance of regulatory compliance of active ingredient manufacturer’s drug master files (DMF) and European certificates of suitability (CEPs). Chuan also has extensive analytical testing and quality control experience, production engineering experience involving trouble shooting, process optimization and long term process / product development activities. Chuan has a wealth of knowledge in regulatory compliance, validations, project management, GMP/GLP/GDP/GVP and regulatory affairs, he has designed and conducted series of training courses to train thousands of industry professional.

Angine Partner in India for BD and supply chain.Vishy is a post-graduate in Pharmacology with about 3 decades experience in sales, marketing, business development and strategic planning in the pharmaceutical industry across Asia.His previous experience includes Serum Institute (Serono) and Astra in India both in sales and marketing, 8 years with Pharmacia in India and China. He was then the BD and Strategic Planning Director for Pfizer China and BD Director - Asia for Capsugel (Division of Pfizer) until 2011 based inBangkok.Currently living inChennai,Vishy play a key role in Angine Partner team for the projects in both innovative drugs and generic drug between China and India.

Angine Partner for Pharmacoeconomics and Health Economy Project. Omar formerly was a health economist with CADTH (the Canadian HTA agency) and a guest lecturer at the National University of Singapore. He brings over 10 years of experience in health economics and market access including insider roles in HTA, consulting and industry. Most recently he was a HEOR Director APAC at a Singaporean consultancy, where he oversaw both HEOR , HTA, RWE, and strategic market access projects in a diverse set of geographies. He also has industry experience where he led HTA submissions, evidence and access strategy and held leadership roles on cross-functional teams. APAC-relevant experience includes multiple HTA submissions in the Philippines and Singapore, large-scale policy-shaping in Thailand, multi-country cohort studies, policy-facing modelling in greater China, pricing and market access strategy in Japan, and multi-country strategy for digital health assets in ASEAN and East Asia. He has also collaborated with the Saudi Health Council on evidence generation strategy and policy-shaping.